Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity| March Biosciences - A clinical-stage cell-therapy company targeting challengi...
March Biosciences has forged a strategic alliance with CTMC, a joint venture between Resilience + MD Anderson Cancer Center. The partnership is focused on the development of March Biosciences' lead asset, MB-105, and advanced cellular therapy currently in clinical studies.| March Biosciences - A clinical-stage cell-therapy company targeting challengi...